KEEP BUT DO NOT DISPLAY

New research shows that young people are most likely to conceal diabetes fearing discrimination or bullying. One-third of people with diabetes are risking ill health by keeping their diabetes secret, according to a survey that found one in three with the condition had concealed it. Almost half felt not talking …

Choosing the right formula could stave off infant diabetes, according to a new global study. The study showed that if a mother transitions from breastfeeding to “highly hydrolyzed formula,” which is broken down for easier digestion, the infant may have a lower risk of developing type 1 diabetes. The study, …

Scientists have developed a promising new strategy for treating human type 2 diabetes which affects more than 200 million people worldwide. In a mouse study, scientists at Mayo Clinic Florida showed that a different approach could also be effective for treating diabetes — namely, blocking the breakdown of insulin, after …

  Germany & France suspend the use of Actos, a TZD diabetes drug, due to worries about a possible link to bladder cancer. Interim results from trials in the U.S. one of which began in 2003 and is slated to last 10 years, have so far not confirmed a clear …

Drinking low-fat chocolate milk after a tough workout provides the right mix of carbohydrates and high-quality protein, U.S. researchers found. Researchers in three related studies compared the recovery benefits of drinking low-fat chocolate milk after exercise to a carbohydrate beverage with the same calories — similar to a typical sports …

Researchers have unexpectedly found evidence that the early stages of metabolic syndrome, insulin resistance, and the accompanying hyperinsulinemia may have favorable effects on lower urinary tract symptoms (LUTS). After analyzing 34,000 men aged 30 and older, they discovered that metabolic syndrome seemed to protect against LUTS. They observed a "marginally …

FDA’s meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs. FDA

Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide See this week’s Item #6, Sanofi’s Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study.

Dr. Christian Holscher and his University of Ulster, Northern Ireland, UK, team have already found the drug can enhance brain cell growth and protect memory formation in mice, as well as reducing levels of amyloid — a hallmark protein in Alzheimer’s — in the brain. The research team focused on …

The risk of depression among patients with diabetes varies depending on age and type of diabetes according to new research. The study investigated the risk of depression according to diabetes treatment, sex and age in the Norwegian population using data from the National Register of Prescriptions, including people being prescribed …